Pharmaron Beijing Co., Ltd.
300759.SZ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$73.63B
Close$
$-1.84
103.7% downside
Current Fair Value
103.7% downsideOvervalued by 103.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $73.63 Billion |
|---|---|
| Enterprise Value | $80.18 Billion |
| Annual dividend | $0.20 |
| Dividend yield | 0.48% |
| Earnings per Share | $0.94 |
| Beta | 0.68 |
| Outstanding Shares | 1,833,937,013 |
Return
| Return on Equity | 10.80% |
|---|---|
| Return on Assets | 6.10% |
| Return on Invested Capital | 11.35% |
Valuation & Multiples
| P/E Ratio | 41.79 |
|---|---|
| PEG | 319.44 |
| Price to Sales | 6.25 |
| Price to Book Ratio | 5.55 |
| Enterprise Value to Revenue | 5.04 |
| Enterprise Value to EBIT | 34.93 |
| Enterprise Value to Net Income | 45 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.5 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 27, 2026
EPS Estimate
$0.29
Consensus analyst estimateRevenue Estimate
$4.36 B
Consensus analyst estimateNext Earnings Call
Expected Date
March 29, 2027
EPS Estimate
$0.44
Consensus analyst estimateRevenue Estimate
$4.79 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Pharmaron Beijing Co., Ltd.
27,316 employees
CEO: Bo Liang Lou
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segment...